Live Breaking News & Updates on Infigratinib

Stay updated with breaking news from Infigratinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Infigratinib Receives Breakthrough Therapy Designation in China for Gastric Cancer

China’s National Medical Products Administration has granted a breakthrough therapy designation to infigratinib for the treatment of patients with gastric cancer. ....

United States , Yizhe Wang , Bridgebio Pharma , Helsinn Birex Pharmaceuticals , United States Securities And Exchange Commission , K Securities And Exchange Commission , China National Medical Products Administration , National Medical Products Administration , Helsinn Healthcare , States Securities And Exchange Commission , Securities And Exchange , Gastrointestinal Cancer , Global Oncology , Chinas National Medical Products Administration , Gastric Cancer ,

Helsinn Healthcare S.A.: Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets Lugano, Switzerland, and Singapore, 04 May 2022 - Juniper ....

United States , Coted Ivoire , Sri Lanka , New Zealand , South Korea , Republic Of , South Africa , United Arab Emirates , Saudi Arabia , Ivory Coast , Twitterand Linkedin , Kostenloser Wertpapierhandel , Raman Singh , Paola Bonvicini , Helsinn Ceocommented , Giorgio Calderari , Gastroenterol Hepatol , European Network For The Study Of Cholangiocarcinoma , Juniper Biologics Pte Ltd , Drug Administration , Helsinn Birex Pharmaceuticals Ltd , Group Head Of Communication , Therapeutics Goods Association , Helsinn Group , Health Canada , Sylvan Group ,

Helsinn Healthcare S.A.: Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive license ....

United States , Hong Kong , Twitterand Linkedin , Paola Bonvicini , Helsinn Bio Pharma , Giorgio Calderari , Neil Kumar , Gastroenterol Hepatol , Katherine Yau , Helsinn Group , Helsinn Birex Pharmaceuticals Ltd , Bridgebio Pharma Inc , Helsinn Group Media Contact , European Network For The Study Of Cholangiocarcinoma , Drug Administration , Exchange Commission , Group Head Of Communication , Therapeutics Goods Association , Bio Pharma Inc , Securities Exchange , Health Canada , Bridgebio Pharma Announce Update , Strategic Collaboration , Commercialize Infigratinib , Oncology Indications , Palo Alto ,

Helsinn Healthcare S.A.: Helsinn Group Announces European Medicines Agency's (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusion

Helsinn Group Announces European Medicines Agency's (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with ....

Hong Kong , Kostenloser Wertpapierhandel , Twitterand Linkedin , Paola Bonvicini , Sergio Cantoreggi , Helsinn Group , Company Marketing Authorization Application , Helsinn Group Announces European Medicinesagency , Health Authorities , Group Head Of Communication , Helsinn Group Media Contact , European Union , European Medicines Agency , Bio Pharma Inc , Health Authority , Marketing Authorization Application , Bridgebio Pharma , Helsinn Group Chief Scientific Officer , Global Head , Group Media Contact ,

BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ (infigratinib) for Patients with Cholangiocarcinoma

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) ....

United States , Hong Kong , Bio Pharma , Susan Moran , Stacie Lindsey , Paola Bonvicini , Milind Javle , Paul Rittman , Ireland Helsinn Birex Pharmaceuticals Ltd , Helsinn Therapeutics Us Inc , Us Helsinn Therapeutics Inc , Oncology Center , Helsinn Group , Swiss Pharma Company , Helsinn Group Media , Therapeutics Inc , Bridgebio Pharma Inc , European Union , B Future Health Fund , Helsinn Investment Fund , University Of Texas Md Anderson Cancer Center , Drug Administration , Risk Factors Bio Pharma Inc , Exchange Commission , China Helsinn Pharmaceuticals Beijing Co Ltd , Group Head Of Communication ,